467 articles across injectables, lasers, body contouring, skin therapeutics, and provider safety.
The FDA's proposed exclusion of semaglutide and tirzepatide from the 503B Bulks List will end industrial GLP-1 compounding in 2026. A guide to legal timelines and…
Cosmetic Botox is excluded from HSA/FSA funds, but therapeutic Botox for migraine, hyperhidrosis, or TMJ qualifies with an LMN and proper coding. A detailed regulatory…
Plasma pens bypass FDA cosmetic reviews, but voluntary MAUDE databases reveal severe risks of atrophic scarring and hypopigmentation requiring costly laser corrections.
Chin implant (FWP) FDA MAUDE analysis: across 237 reports patient injury dominates and infection is the leading complication theme — with the caveats MAUDE demands.
FDA warnings on needle-free dermal filler devices (Hyaluron Pens). High-pressure jet injection carries severe risks of skin necrosis, permanent blindness, and clinical…
A comprehensive guide to California's strict laser hair removal regulations: medical board scope-of-practice rules, eligible providers, esthetician prohibitions, and…
How aesthetic devices clear the SFDA — Class A–D classification, the GHAD portal and MDMA pathway, the Local Authorized Representative requirement, and Saudi market…
A comprehensive guide to Florida laser hair removal licensing in 2026. Learn about the Electrolysis Council, Rule 64B8-56.002, and supervision rules.
A complete guide to the TDLR laser hair removal licensing system in Texas for 2026. Learn about the 4 tiers, facility registration, and renewal rules.
A clinical and regulatory analysis of surgical smoke hazards in aesthetic medicine, covering OSHA enforcement, state laws, NIOSH hierarchy of controls, and smoke…